Jazz Pharmaceuticals plc (JAZZ) 10-Year Financial Performance & Capital Metrics

JAZZ • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersPsychiatric & CNS Disorders

AboutJazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.Show more

Revenue $4.07B +6.1%
EBITDA $1.38B +13.1%
Net Income $560M +35.0%
EPS (Diluted) 8.65 +41.8%
Gross Margin 89.05% +0.5%
EBITDA Margin 33.83% +6.6%
Operating Margin 17.61% +16.7%
Net Margin 13.77% +27.2%
ROE 14.31% +17.6%
ROIC 6.78% +25.2%
Debt/Equity 1.51 -2.9%
Interest Coverage 3.01 +50.6%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong Piotroski F-Score: 8/9
✓FCF machine: 33.1% free cash flow margin
✓Momentum leader: RS Rating 82 (top 18%)
✓High quality earnings: Operating CF exceeds net income
✓Strong 5Y sales CAGR of 13.5%
✓Share count reduced 8.4% through buybacks

✗Weaknesses

No significant weaknesses identified

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y13.25%

5Y13.48%

3Y9.56%

TTM4.14%

Profit (Net Income) CAGR

10Y25.37%

5Y1.37%

3Y-

TTM-179.56%

EPS CAGR

10Y24.98%

5Y-0.99%

3Y-

TTM-185.49%

ROCE

10Y Avg8.72%

5Y Avg4.18%

3Y Avg4.04%

Latest6.88%

Peer Comparison

Psychiatric & CNS Disorders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
JAZZJazz Pharmaceuticals plc	10.4B	171.16	19.79	6.12%	-8.86%	-9.31%	12.96%	1.51
ACADACADIA Pharmaceuticals Inc.	4.49B	26.53	19.51	31.85%	24.94%	28.47%	3.5%	0.07
CPRXCatalyst Pharmaceuticals, Inc.	2.82B	22.96	17.53	23.49%	37.63%	23.64%	8.48%	0.00
HRMYHarmony Biosciences Holdings, Inc.	2.1B	36.41	14.51	22.8%	22.48%	22.23%	10.43%	0.28
ALKSAlkermes plc	5.15B	31.22	14.39	-6.36%	22.27%	19.55%	7.87%	0.05
PRTCPureTech Health plc	463.31M	19.17	9.59	44.98%	-495.91%	-8.53%		0.05
LBRXLB Pharmaceuticals Inc Common Stock	540.89M	21.38	-1.20
NMRANeumora Therapeutics, Inc. Common Stock	361.97M	2.13	-1.39			-178.79%		0.01

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	1.32B	1.49B	1.62B	1.89B	2.16B	2.36B	3.09B	3.66B	3.83B	4.07B
Revenue Growth %	0.13%	0.12%	0.09%	0.17%	0.14%	0.09%	0.31%	0.18%	0.05%	0.06%
Cost of Goods Sold+	102.53M	105.39M	110.19M	121.54M	127.93M	148.92M	440.76M	540.52M	435.58M	445.71M
COGS % of Revenue	0.08%	0.07%	0.07%	0.06%	0.06%	0.06%	0.14%	0.15%	0.11%	0.11%
Gross Profit+	1.22B	1.38B	1.51B	1.77B	2.03B	2.21B	2.65B	3.12B	3.4B	3.62B
Gross Margin %	0.92%	0.93%	0.93%	0.94%	0.94%	0.94%	0.86%	0.85%	0.89%	0.89%
Gross Profit Growth %	0.16%	0.13%	0.09%	0.17%	0.15%	0.09%	0.2%	0.18%	0.09%	0.07%
Operating Expenses+	714.06M	790.93M	979.66M	1.15B	1.5B	1.84B	2.48B	3.18B	2.82B	2.91B
OpEx % of Revenue	0.54%	0.53%	0.61%	0.61%	0.69%	0.78%	0.8%	0.87%	0.74%	0.71%
Selling, General & Admin	449.12M	502.89M	544.16M	683.53M	736.94M	854.23M	1.45B	1.42B	1.34B	1.39B
SG&A % of Revenue	0.34%	0.34%	0.34%	0.36%	0.34%	0.36%	0.47%	0.39%	0.35%	0.34%
Research & Development	135.25M	162.3M	198.44M	226.62M	299.73M	335.38M	505.75M	590.45M	849.66M	884M
R&D % of Revenue	0.1%	0.11%	0.12%	0.12%	0.14%	0.14%	0.16%	0.16%	0.22%	0.22%
Other Operating Expenses	129.69M	125.74M	237.06M	244.39M	464.79M	646.97M	525.77M	1.18B	627.28M	637.31M
Operating Income+	508.22M	591.65M	528.84M	614.84M	532.37M	378.07M	170.28M	-65.53M	578.58M	716.63M
Operating Margin %	0.38%	0.4%	0.33%	0.33%	0.25%	0.16%	0.06%	-0.02%	0.15%	0.18%
Operating Income Growth %	1.6%	0.16%	-0.11%	0.16%	-0.13%	-0.29%	-0.55%	-1.38%	9.83%	0.24%
EBITDA+	616.28M	705.43M	694M	831.57M	902.53M	656.33M	722.76M	563.94M	1.22B	1.38B
EBITDA Margin %	0.47%	0.47%	0.43%	0.44%	0.42%	0.28%	0.23%	0.15%	0.32%	0.34%
EBITDA Growth %	0.87%	0.14%	-0.02%	0.2%	0.09%	-0.27%	0.1%	-0.22%	1.16%	0.13%
D&A (Non-Cash Add-back)	108.06M	113.78M	165.15M	216.73M	370.16M	278.25M	552.48M	629.47M	638.7M	660.07M
EBIT	557.91M	640.1M	613.84M	715.93M	642.35M	765.46M	475.26M	839.14M	810.73M	861.64M
Net Interest Income+	-56.92M	-61.94M	-77.76M	-78.5M	-72.26M	-99.71M	-278.77M	-288.24M	-289.44M	-238.1M
Interest Income	0	0	0	0	0	0	0	0	0	0
Interest Expense	56.92M	61.94M	77.76M	78.5M	72.26M	99.71M	278.77M	288.24M	289.44M	238.1M
Other Income/Expense	-72.29M	-59.59M	-88.73M	-87.58M	-82.16M	-105.94M	-283.83M	-317.18M	-283.66M	-247.94M
Pretax Income+	435.93M	532.07M	440.11M	527.26M	450.21M	272.13M	-113.55M	-382.7M	294.92M	468.69M
Pretax Margin %	0.33%	0.36%	0.27%	0.28%	0.21%	0.12%	-0.04%	-0.1%	0.08%	0.12%
Income Tax+	106.4M	135.24M	-47.74M	80.16M	-73.15M	33.52M	216.12M	-158.65M	-119.91M	-91.43M
Effective Tax Rate %	0.76%	0.75%	1.11%	0.85%	1.16%	0.88%	2.9%	0.59%	1.41%	1.2%
Net Income+	329.54M	396.83M	487.85M	447.1M	523.37M	238.62M	-328.95M	-224.06M	414.83M	560.12M
Net Margin %	0.25%	0.27%	0.3%	0.24%	0.24%	0.1%	-0.11%	-0.06%	0.11%	0.14%
Net Income Growth %	4.64%	0.2%	0.23%	-0.08%	0.17%	-0.54%	-2.38%	0.32%	2.85%	0.35%
Net Income (Continuing)	329.53M	396.83M	487.85M	447.1M	523.37M	238.62M	-329.67M	-224.06M	414.83M	560.12M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	5.23	6.41	7.96	7.30	9.09	4.22	-5.51	-3.58	6.10	8.65
EPS Growth %	4.62%	0.23%	0.24%	-0.08%	0.25%	-0.54%	-2.31%	0.35%	2.7%	0.42%
EPS (Basic)	5.38	6.56	8.13	7.45	9.22	4.28	-5.51	-3.58	6.55	9.06
Diluted Shares Outstanding	63.04M	61.87M	61.32M	61.22M	57.55M	56.52M	59.69M	62.54M	72.07M	66.01M
Basic Shares Outstanding	61.23M	60.5M	60.02M	59.98M	56.75M	55.71M	59.69M	62.54M	63.29M	61.84M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	1.26B	748.07M	968.28M	1.23B	1.63B	2.84B	2.61B	2.61B	3.44B	4.63B
Cash & Short-Term Investments	988.78M	425.96M	601.03M	824.62M	1.08B	2.13B	591.45M	881.48M	1.63B	2.99B
Cash Only	988.78M	365.96M	386.04M	309.62M	637.34M	1.06B	591.45M	881.48M	1.51B	2.41B
Short-Term Investments	0	60M	215M	515M	440M	1.07B	0	0	120M	580M
Accounts Receivable	209.69M	234.24M	224.13M	263.84M	355.99M	396.49M	563.36M	651.49M	705.79M	716.76M
Days Sales Outstanding	57.77	57.46	50.54	50.93	60.11	61.23	66.45	64.98	67.19	64.3
Inventory	19.45M	34.05M	43.24M	52.96M	78.61M	95.4M	1.07B	714.06M	597.04M	480.44M
Days Inventory Outstanding	69.25	117.93	143.25	159.03	224.28	233.82	888.34	482.19	500.3	393.44
Other Current Assets	19.05M	29.31M	76.69M	67.57M	78.89M	152.49M	252.39M	267.19M	320.81M	261.54M
Total Non-Current Assets+	2.1B	4.05B	4.16B	3.97B	3.91B	3.7B	9.69B	8.23B	7.96B	7.38B
Property, Plant & Equipment	85.57M	107.49M	170.08M	200.36M	270.89M	257.1M	343.42M	301.38M	234.99M	227M
Fixed Asset Turnover	15.48x	13.84x	9.52x	9.44x	7.98x	9.19x	9.01x	12.14x	16.32x	17.93x
Goodwill	657.14M	893.81M	947.54M	927.63M	920.02M	958.3M	1.83B	1.69B	1.75B	1.72B
Intangible Assets	1.19B	3.01B	2.98B	2.73B	2.44B	2.2B	7.15B	5.79B	5.42B	4.76B
Long-Term Investments	0	0	0	0	0	0	0	0	0	4.33M
Other Non-Current Assets	16.48M	23.8M	24.09M	52.28M	55.34M	30.96M	52.84M	64.39M	73.94M	119.64M
Total Assets+	3.36B	4.8B	5.12B	5.2B	5.54B	6.54B	12.3B	10.84B	11.39B	12.01B
Asset Turnover	0.39x	0.31x	0.32x	0.36x	0.39x	0.36x	0.25x	0.34x	0.34x	0.34x
Asset Growth %	0.01%	0.43%	0.07%	0.02%	0.06%	0.18%	0.88%	-0.12%	0.05%	0.05%
Total Current Liabilities+	226.64M	257.41M	293.95M	345.49M	364.49M	653.75M	809.3M	933.19M	1.54B	1.04B
Accounts Payable	21.81M	22.41M	24.37M	40.6M	47.55M	26.95M	100.3M	90.76M	102.75M	77.87M
Days Payables Outstanding	77.63	77.63	80.72	121.93	135.65	66.04	83.06	61.29	86.1	63.77
Short-Term Debt	37.59M	36.09M	40.6M	33.39M	33.39M	246.32M	31M	31M	604.95M	31M
Deferred Revenue (Current)	1000K	1000K	1000K	1000K	1000K	1000K	1000K	463K	0	0
Other Current Liabilities	41.7M	47.73M	63.99M	62.51M	85.03M	124.59M	193.1M	169.41M	142.32M	189.76M
Current Ratio	5.55x	2.91x	3.29x	3.57x	4.47x	4.34x	3.23x	2.79x	2.24x	4.46x
Quick Ratio	5.46x	2.77x	3.15x	3.42x	4.26x	4.20x	1.90x	2.03x	1.85x	3.99x
Cash Conversion Cycle	49.38	97.76	113.07	88.03	148.73	229	871.73	485.89	481.39	393.97
Total Non-Current Liabilities+	1.53B	2.67B	2.12B	2.1B	2.06B	2.22B	7.52B	6.82B	6.12B	6.88B
Long-Term Debt	1.15B	1.99B	1.54B	1.56B	1.57B	1.85B	6.02B	5.69B	5.11B	6.08B
Capital Lease Obligations	0	0	0	0	151.23M	140.03M	87.2M	71.84M	59.23M	38.94M
Deferred Tax Liabilities	294.49M	556.73M	383.47M	309.1M	224.09M	130.4M	1.3B	944.34M	847.71M	676.74M
Other Non-Current Liabilities	69.25M	112.62M	176.61M	218.88M	109.37M	101.15M	117M	106.81M	104.75M	86.61M
Total Liabilities	1.76B	2.92B	2.41B	2.45B	2.43B	2.88B	8.33B	7.75B	7.66B	7.92B
Total Debt+	1.19B	2.03B	1.58B	1.6B	1.77B	2.25B	6.15B	5.81B	5.79B	6.16B
Net Debt	199.66M	1.66B	1.2B	1.29B	1.13B	1.19B	5.56B	4.93B	4.29B	3.75B
Debt / Equity	0.74x	1.08x	0.58x	0.58x	0.57x	0.61x	1.55x	1.88x	1.55x	1.51x
Debt / EBITDA	1.93x	2.88x	2.28x	1.92x	1.96x	3.43x	8.51x	10.31x	4.76x	4.48x
Net Debt / EBITDA	0.32x	2.36x	1.72x	1.55x	1.26x	1.82x	7.69x	8.74x	3.52x	2.72x
Interest Coverage	8.93x	9.55x	6.80x	7.83x	7.37x	3.79x	0.61x	-0.23x	2.00x	3.01x
Total Equity+	1.6B	1.88B	2.71B	2.76B	3.11B	3.66B	3.97B	3.09B	3.74B	4.09B
Equity Growth %	0.17%	0.17%	0.45%	0.02%	0.13%	0.18%	0.08%	-0.22%	0.21%	0.1%
Book Value per Share	25.36	30.34	44.25	45.04	54.06	64.75	66.43	49.34	51.86	62.02
Total Shareholders' Equity	1.6B	1.88B	2.71B	2.76B	3.11B	3.66B	3.97B	3.09B	3.74B	4.09B
Common Stock	61K	61K	61K	61K	61K	61K	61K	61K	61K	61K
Retained Earnings	302.69M	528.91M	917.96M	841.05M	1.07B	1.16B	830.23M	733.59M	878.66M	1.13B
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-267.47M	-317.33M	-140.88M	-197.79M	-223.39M	-134.35M	-400.36M	-1.13B	-842.15M	-947.67M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	531.94M	590.54M	693.09M	798.9M	776.4M	899.65M	778.51M	1.27B	1.09B	1.4B
Operating CF Margin %	0.4%	0.4%	0.43%	0.42%	0.36%	0.38%	0.25%	0.35%	0.28%	0.34%
Operating CF Growth %	0.31%	0.11%	0.17%	0.15%	-0.03%	0.16%	-0.13%	0.63%	-0.14%	0.28%
Net Income	329.53M	396.83M	487.85M	447.1M	523.37M	238.62M	-329.67M	-224.06M	414.83M	560.12M
Depreciation & Amortization	108.06M	113.78M	165.15M	216.73M	370.16M	278.25M	552.48M	629.47M	638.7M	660.07M
Stock-Based Compensation	91.55M	98.77M	106.9M	102.44M	110.56M	121M	189.01M	222M	226.84M	248.04M
Deferred Taxes	-61.21M	-41.16M	-225.59M	-88.81M	-236.61M	-136.94M	69.2M	-292.25M	-260.22M	-208.33M
Other Non-Cash Items	70.12M	45.04M	132.01M	98.16M	159.01M	484.15M	345.44M	926.92M	276.29M	212.72M
Working Capital Changes	-6.11M	-22.72M	26.77M	23.29M	-150.08M	-85.44M	-47.95M	9.9M	-204.44M	-76.72M
Change in Receivables	-24.84M	-25.6M	12.28M	-40.13M	-92.33M	-38.65M	-92.73M	-90.14M	0	-21.11M
Change in Inventory	6.27M	-17.02M	-8.67M	-18.51M	-32.79M	-30.54M	-48.86M	-49.64M	0	-45.54M
Change in Payables	-2.28M	361K	214K	17.04M	4.77M	-18.93M	57.02M	-11.22M	9.6M	-20.07M
Cash from Investing+	-2.25M	-1.75B	-268.95M	-394.49M	-155.3M	-1.01B	-5.21B	-446.23M	-163.06M	-508.19M
Capital Expenditures	-35.96M	-181.58M	-113.95M	-131.47M	-182.34M	-379.25M	-27.64M	-498.19M	-23.96M	-38.07M
CapEx % of Revenue	0.03%	0.12%	0.07%	0.07%	0.08%	0.16%	0.01%	0.14%	0.01%	0.01%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	33.7M	-173.75M	-85M	-63.2M	101.33M	378.51M	-17.89M	0	-19M	-10M
Cash from Financing+	-214.32M	540.99M	-409.11M	-479.13M	-293.75M	528.07M	3.97B	-529.49M	-305.25M	20.52M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-26.18M	24.17M	16.39M	-23.08M	-16.74M	99.68M	99.66M	-45.44M	-4.49M	-42.82M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	495.99M	408.95M	579.14M	667.43M	594.07M	520.39M	732.98M	773.78M	1.07B	1.35B
FCF Margin %	0.37%	0.27%	0.36%	0.35%	0.27%	0.22%	0.24%	0.21%	0.28%	0.33%
FCF Growth %	1.97%	-0.18%	0.42%	0.15%	-0.11%	-0.12%	0.41%	0.06%	0.38%	0.26%
FCF per Share	7.87	6.61	9.44	10.90	10.32	9.21	12.28	12.37	14.82	20.42
FCF Conversion (FCF/Net Income)	1.61x	1.49x	1.42x	1.79x	1.48x	3.77x	-2.37x	-5.68x	2.63x	2.49x
Interest Paid	40.1M	39.9M	44.61M	42.71M	43M	42.47M	138.27M	270.67M	333.11M	314.82M
Taxes Paid	145.6M	160.31M	174.12M	164.22M	183.61M	226.82M	271.22M	94.68M	177.88M	114.91M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	22.19%	22.83%	21.25%	16.35%	17.84%	7.05%	-8.63%	-6.36%	12.16%	14.31%
Return on Invested Capital (ROIC)	19.92%	16.62%	10.65%	11.6%	9.63%	6.23%	1.78%	-0.56%	5.41%	6.78%
Gross Margin	92.26%	92.92%	93.19%	93.57%	94.08%	93.7%	85.76%	85.23%	88.64%	89.05%
Net Margin	24.87%	26.67%	30.14%	23.64%	24.21%	10.1%	-10.63%	-6.12%	10.82%	13.77%
Debt / Equity	0.74x	1.08x	0.58x	0.58x	0.57x	0.61x	1.55x	1.88x	1.55x	1.51x
Interest Coverage	8.93x	9.55x	6.80x	7.83x	7.37x	3.79x	0.61x	-0.23x	2.00x	3.01x
FCF Conversion	1.61x	1.49x	1.42x	1.79x	1.48x	3.77x	-2.37x	-5.68x	2.63x	2.49x
Revenue Growth	12.95%	12.32%	8.79%	16.82%	14.32%	9.34%	30.91%	18.26%	4.78%	6.12%

Revenue by Segment

	2014	2015	2016	2017	2018	2019	2020	2021	2022	2024
Xywav	-	-	-	-	-	-	15.26M	535.3M	958.42M	1.47B
Xywav Growth	-	-	-	-	-	-	-	3406.92%	79.05%	53.71%
Epidiolex/Epidyolex	-	-	-	-	-	-	-	463.64M	736.4M	972.42M
Epidiolex/Epidyolex Growth	-	-	-	-	-	-	-	-	58.83%	32.05%
Rylaze/Enrylaze	-	-	-	-	-	-	-	85.63M	281.66M	410.85M
Rylaze/Enrylaze Growth	-	-	-	-	-	-	-	-	228.93%	45.87%
Zepzelca	-	-	-	-	-	-	90.38M	246.81M	269.91M	320.32M
Zepzelca Growth	-	-	-	-	-	-	-	173.08%	9.36%	18.67%
Xyrem	778.58M	955.19M	-	1.19B	1.4B	1.64B	1.74B	1.27B	1.02B	233.82M
Xyrem Growth	-	22.68%	-	-	18.38%	16.92%	6.04%	-27.32%	-19.38%	-77.09%
High Sodium AG Oxybate Product Royalty Revenue	-	-	-	-	-	-	-	-	-	217.57M
High Sodium AG Oxybate Product Royalty Revenue Growth	-	-	-	-	-	-	-	-	-	-
Defitelio/Defibrotide	-	-	-	-	149.45M	172.94M	195.84M	197.93M	194.29M	216.56M
Defitelio/Defibrotide Growth	-	-	-	-	-	15.72%	13.24%	1.07%	-1.84%	11.46%
Vyxeos	-	-	-	33.79M	100.83M	121.41M	121.11M	134.06M	127.98M	162.59M
Vyxeos Growth	-	-	-	-	198.42%	20.40%	-0.25%	10.70%	-4.54%	27.05%
Sativex	-	-	-	-	-	-	-	12.71M	16.82M	18.88M
Sativex Growth	-	-	-	-	-	-	-	-	32.41%	12.20%
Other Products	-	-	-	22.56M	18.75M	17.55M	6.84M	9.8M	6.64M	11.47M
Other Products Growth	-	-	-	-	-16.90%	-6.37%	-61.02%	43.20%	-32.20%	72.68%
Ziihera	-	-	-	-	-	-	-	-	-	1.05M
Ziihera Growth	-	-	-	-	-	-	-	-	-	-
Product And Services, Product Sales Net Of Deductions	-	-	-	-	-	-	2.35B	-	-	-
Product And Services, Product Sales Net Of Deductions Growth	-	-	-	-	-	-	-	-	-	-
Neuroscience	-	-	-	-	-	-	1.79B	-	-	-
Neuroscience Growth	-	-	-	-	-	-	-	-	-	-
Total Oxybate	-	-	-	-	-	-	1.76B	-	-	-
Total Oxybate Growth	-	-	-	-	-	-	-	-	-	-
Oncology	-	-	-	-	-	-	554.46M	-	-	-
Oncology Growth	-	-	-	-	-	-	-	-	-	-
Erwinaze And Erwinase	199.66M	203.26M	-	197.34M	174.74M	177.47M	147.14M	-	-	-
Erwinaze And Erwinase Growth	-	1.80%	-	-	-11.45%	1.56%	-17.09%	-	-	-
Sunosi	-	-	-	-	-	3.71M	28.33M	-	-	-
Sunosi Growth	-	-	-	-	-	-	662.87%	-	-	-
Product And Services, Royalties And Contract Revenue	-	-	-	-	21.45M	26.16M	16.91M	-	-	-
Product And Services, Royalties And Contract Revenue Growth	-	-	-	-	-	21.96%	-35.37%	-	-	-
Product And Services, Product Sales	-	-	-	-	1.87B	2.14B	-	-	-	-
Product And Services, Product Sales Growth	-	-	-	-	-	14.24%	-	-	-	-
Prialt	26.42M	26.44M	-	27.36M	20.84M	-	-	-	-	-
Prialt Growth	-	0.07%	-	-	-23.84%	-	-	-	-	-
Defitelio	70.54M	70.73M	108.95M	133.65M	-	-	-	-	-	-
Defitelio Growth	-	0.28%	54.04%	22.67%	-	-	-	-	-	-
Psychiatry	40.88M	37.13M	-	-	-	-	-	-	-	-
Psychiatry Growth	-	-9.16%	-	-	-	-	-	-	-	-
Others	46.63M	24.07M	-	-	-	-	-	-	-	-
Others Growth	-	-48.39%	-	-	-	-	-	-	-	-

Revenue by Geography

	2014	2015	2016	2017	2018	2019	2020	2021	2022	2024
UNITED STATES	1.01B	1.19B	1.35B	1.46B	1.73B	1.97B	2.14B	2.82B	3.37B	3.66B
UNITED STATES Growth	-	18.41%	13.58%	8.01%	18.05%	13.76%	9.12%	31.51%	19.51%	8.60%
Europe	126.72M	103.61M	106.15M	122.79M	125.91M	150.2M	175.21M	230.16M	239.64M	312.71M
Europe Growth	-	-18.23%	2.44%	15.68%	2.54%	19.29%	16.65%	31.36%	4.12%	30.49%
Other Countries	-	28.31M	26.91M	32.45M	37.44M	46.24M	43.82M	43.84M	49.36M	96.14M
Other Countries Growth	-	-	-4.96%	20.59%	15.37%	23.53%	-5.24%	0.05%	12.59%	94.77%

Frequently Asked Questions

Valuation & Price

Jazz Pharmaceuticals plc (JAZZ) has a price-to-earnings (P/E) ratio of 19.8x. This is roughly in line with market averages.

Growth & Financials

Jazz Pharmaceuticals plc (JAZZ) reported $4.16B in revenue for fiscal year 2024. This represents a 1427% increase from $272.3M in 2011.

Jazz Pharmaceuticals plc (JAZZ) grew revenue by 6.1% over the past year. This is steady growth.

Jazz Pharmaceuticals plc (JAZZ) reported a net loss of $368.5M for fiscal year 2024.

Dividend & Returns

Jazz Pharmaceuticals plc (JAZZ) has a return on equity (ROE) of 14.3%. This is reasonable for most industries.

Jazz Pharmaceuticals plc (JAZZ) generated $1.34B in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...